Tarsus Pharmaceuticals, Inc. TARS
67.52 USD -1.55 (-2.24%)
At closeNov 5, 2026, 4:13 PM EST
67.52 0.00 0.00%
After hours · Nov 5, 4:13 PM ET
66.85 Day range 70.94
53.89 52-week range 91.53
- YTD
- -17.54%
- 1 year
- -1.00%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 99.33 +47.1% upside
Now 67.52
- Target (low)
- 88.00
- Target (mean)
- 99.33
- Target (high)
- 116.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -4.82 | -9.57 – -0.07 | -0.20 | -2310.0% | 210.36M | +38.7% | 2 |
| Next quarter | -0.56 | -0.56 – -0.56 | -0.16 | -250.0% | 198.17M | +22.3% | 1 |
| Current year | -5.79 | -11.63 – -2.52 | -1.59 | -264.4% | 738.56M | +63.6% | 3 |
| Next year | -0.50 | -1.59 – 1.04 | -5.79 | +91.4% | 920.04M | +24.6% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 8, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 12, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 20, 2025 | Mizuho | Initiated | — | Outperform |
| Nov 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Oct 20, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 5, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 2, 2025 | Guggenheim | Maintained | Buy | Buy |
| Mar 6, 2025 | Jefferies | Maintained | Buy | Buy |
| Feb 26, 2025 | Guggenheim | Maintained | Buy | Buy |
| Feb 26, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 26, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jan 27, 2025 | Barclays | Maintained | Overweight | Overweight |
| Jan 22, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 15, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 14, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 9, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 10, 2024 | Barclays | Maintained | Overweight | Overweight |
| May 9, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 6, 2024 | Jefferies | Maintained | Buy | Buy |